Cannara Biotech's Recent Accomplishments
Cannara Biotech Inc. is making headlines for not just its quality cannabis products but also its strategic financial maneuvers. The company has recently made promising strides by significantly reducing its cost of debt and being recognized for its outstanding brand in the cannabis market.
Recognition as Brand of the Year
At a high-profile event in Toronto, the 6th Annual Grow Up Awards Gala, Cannara was honored with the coveted Brand of the Year award for its Tribal brand of cannabis. This recognition signifies a prestigious acknowledgment of the company’s dedication to maintaining product excellence in the competitive cannabis landscape. In addition to this accolade, Cannara's Nugz Happle product was also awarded Accessory of the Year, showcasing the company's innovative approach to cannabis products.
A Commitment to Excellence
“Receiving these awards is a testament to our unwavering commitment to delivering premium cannabis at affordable prices,” stated Zohar Krivorot, Cannara’s President and CEO. He emphasized the importance of brand presence and the strategic genetic strategies that have led Cannara to establish itself as a leader in the cannabis market.
Strategic Financial Management
In addition to gaining awards, Cannara has actively worked to enhance its financial position. This involves a partial repayment of its Olymbec convertible debenture and securing a lower interest rate on its BMO credit facility.
Details on Olymbec Convertible Debenture Repayment
Recently, Cannara announced a $1 million repayment against its outstanding Olymbec convertible debenture, originally issued in 2021 and amended multiple times since. This move is part of Cannara's disciplined approach to managing its capital structure, focusing on reducing leverage and enhancing financial flexibility.
Improvements in Interest Rates
Further bolstering its financial health, Cannara successfully negotiated a total reduction of 50 basis points on the interest rate spread related to its BMO Credit Facility. This reduction, achieved through an amendment to the credit agreement coupled with meeting certain performance thresholds, signifies a commendable effort in maintaining competitive financial management.
Current Financial Position
As a result of these strategic decisions, Cannara’s overall cost of debt is now reported to be below 6%. This is a significant marker of the company's financial stability, reflecting its strong performance and careful oversight in managing its resources.
About Cannara Biotech
Cannara Biotech Inc. is recognized as a vertically integrated producer of premium cannabis products, primarily serving the Canadian market. Utilizing two large-scale facilities in Québec that total over 1,650,000 square feet, the company is capable of producing up to 100,000 kilograms of cannabis annually. Thanks to favorable electricity costs in the region, Cannara can offer high-quality products at competitive prices while maintaining strict quality control throughout its cultivation and production processes.
Frequently Asked Questions
What awards did Cannara Biotech recently win?
Cannara Biotech was awarded Brand of the Year and Accessory of the Year at the 2025 Grow Up Awards for their Tribal brand and Nugz Happle product.
How has Cannara Biotech improved its financial situation?
The company reduced its debt by repaying part of its convertible debenture and secured a lower interest rate on its credit facility.
Where are Cannara's facilities located?
Cannara has two large facilities based in Québec, covering over 1.65 million square feet.
What is Cannara's production capacity?
Cannara can potentially produce up to 100,000 kilograms of cannabis annually, leveraging low electricity costs in Québec for better pricing.
Who leads Cannara Biotech?
The company is led by Zohar Krivorot as President and CEO and Nicholas Sosiak as CFO, both of whom emphasize innovation and strategic management in their operations.
